3:46 PM
 | 
Nov 09, 2017
 |  BC Extra  |  Company News

FDA approves Dynavax's HBV vaccine

Dynavax Technologies Corp. (NASDAQ:DVAX) gained $3 (15%) to $23.05 in after-hours trading Thursday after FDA approved Heplisav-B to prevent infection caused by all known subtypes of HBV in adults ages 18 and older. The...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >